ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Quantum Leap Healthcare Collaborative™ (“Quantum Leap”) today announced that ALX Oncology’s next generation CD47 blocker, evorpacept, has been selected for a new investigational treatment arm in the I-SPY-P1 TRIAL for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer.

Laura Esserman, MD, Co-founder of Quantum Leap Healthcare Collaborative and Professor at UCSF, will speak at the TIME 100 Health Summit

Quantum Leap Healthcare Collaborative is pleased to announce that co-founder Dr. Laura Esserman will be among the speakers of the first-ever TIME 100 Health Summit, which will convene individuals from the TIME 100 community and prominent figures in healthcare to highlight essential perspectives on health and wellness, and to encourage cross-disciplinary collaboration toward a better, healthier world.